Tonsillectomy has been considered a treatment for IgA nephropathy (IgAN). It is aimed at removing a source of pathogens, reducing mucosa-associated lymphoid tissue and decreasing polymeric IgA synthesis. However, its beneficial effect is still controversial. In Asia, favorable outcomes have been claimed mostly in association with corticosteroids. In Europe, small, single-center uncontrolled studies have failed to show benefits.
Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy / Feehally, J., Coppo, R., Troyanov, S., Bellur, S.S., Cattran, D., Cook, T., Roberts, I.S.D., Verhave, J.C., Camilla, R., Vergano, L., Egido, J., Wiecek, A., Karkoszka, H., Tesar, V., Maixnerova, D., Ots Rosenberg, M., Quaglia, M., Rollino, C., Magistroni, R., Cusinato, S., et al.. - In: NEPHRON JOURNALS. - ISSN 1660-8151. - 132:1(2016), pp. 15-24. [10.1159/000441852]
Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy
MAGISTRONI, Riccardo;
2016
Abstract
Tonsillectomy has been considered a treatment for IgA nephropathy (IgAN). It is aimed at removing a source of pathogens, reducing mucosa-associated lymphoid tissue and decreasing polymeric IgA synthesis. However, its beneficial effect is still controversial. In Asia, favorable outcomes have been claimed mostly in association with corticosteroids. In Europe, small, single-center uncontrolled studies have failed to show benefits.
| File | Dimensione | Formato | |
|---|---|---|---|
|
441852.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
512.51 kB
Formato
Adobe PDF
|
512.51 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
